China: A new study, published in Diabetes, Metabolic Syndrome and Obesity, has shed light on the potential role of specific ...

A new study published in the journal of Diabetes Research and Clinical Practice showed that higher stroke risk is associated ...

Fecal microbiota analysis of pregnant women may provide early identification of those at risk for gestational diabetes.

Discover a study highlighting the high prevalence of MASLD and liver fibrosis in patients with type 2 diabetes using ...

Biocon Biologics receives USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog, expanding their insulin ...

Apart from simple diagnosis, the study takes an important step toward predictive health monitoring by modeling the risk of ...

Biocon Biologics receives USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog. This rapid-acting insulin ...

Aging men aren't just battling time—they're up against rising blood sugar. New research reveals that subtle increases in ...

Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...

Biocon bagged US FDA's approval for Kristy, which is a rapid-acting human insulin analog, indicated to improve glycemic control in patients with diabetes mellitus.

Biocon Biologics Ltd today announced that the U.S. Food and Drug Administration has approved Kirsty™ (Insulin Aspart-xjhz), ...

Researchers are working to launch a first-in-human clinical trial to test the approach in patients with cancer who develop diabetes after immunotherapy.